Prenetics Ltd Stock Price, News & Analysis

Prenetics (NASDAQ: PRE) completed the divestment of ACT for $72 million, receiving $39.9 million in cash upfront and an additional $6.3 million held in escrow payable over 18 months, bringing total transaction proceeds to $46 million. The company says this lifts cash reserves to over $60 million (excluding Bitcoin) and leaves Prenetics debt-free. Prenetics is reallocating resources to its consumer health brand IM8, which is on pace to reach an $100 million ARR within its first 12 months. The company also reports a Bitcoin treasury of 255.4 BTC valued at $31.6 million (investment cost $27.8 million), an unrealized profit of $3.86 million (13.9% return), and a 1 BTC/day purchase policy since August 1, 2025.

Prenetics Global Limited (NASDAQ: PRE), a consumer health sciences company, announced CEO Danny Yeung will deliver a keynote at Token 2049 in Singapore on October 2, 2025. The presentation will focus on IM8, their supplement brand, and their Bitcoin treasury strategy.

The company currently holds 248.42 BTC at an average price of $108,600 per BTC, with a strategy to acquire 1 Bitcoin daily. Their supplement brand IM8 is projected to achieve $100 million in annual recurring revenue within its first year. Prenetics maintains a strong financial position with $63.5 million in current assets, including $46.3 million from ACT Genomics divestment, $17.2 million in cash, and other assets.

Prenetics (NASDAQ: PRE) reported strong Q2 2025 financial results, with revenue surging 594.9% YoY to $17.7 million. The company's flagship brand IM8 achieved $5.9 million in monthly revenue for August 2025, demonstrating a remarkable 3,100% CAGR since December 2024.

Key financial metrics include gross profit of $7.3 million (up 233.5% YoY) and adjusted EBITDA loss of $(4.1) million. The company maintains a strong balance sheet with $90.3 million in adjusted current assets, including $63.5 million cash. Notably, Prenetics has implemented a Bitcoin treasury strategy, accumulating 228.42 BTC valued at $26.1 million.

The company raised its FY2025 revenue guidance to $85-100 million and expects to achieve break-even by Q1 2026. IM8's strong performance is supported by partnerships with David Beckham and Aryna Sabalenka, with over 300,000 customer orders and 8 million product servings delivered to date.

Prenetics Global Limited (NASDAQ: PRE) celebrates as their global ambassador and shareholder, World No. 1 tennis player Aryna Sabalenka, successfully defends her US Open championship title. Sabalenka becomes the first woman since Serena Williams in 2014 to achieve this feat, marking her fourth Grand Slam victory.

The company's premium supplement brand IM8, co-founded by David Beckham, has shown remarkable growth since its December 2024 launch, with over 300,000 customer purchases and 6 million servings delivered. An AI-powered advertisement featuring Sabalenka has garnered 233 million Instagram views and is being displayed on Times Square billboards during the US Open.

IM8's Daily Ultimate Essentials, which is NSF Certified for Sport, combines 92 essential nutrients and replaces 16 individual supplements in a single drink format.

Prenetics Global Limited (NASDAQ: PRE) announced that world No. 1 tennis star Aryna Sabalenka has joined IM8 Health as both global ambassador and shareholder, marking the first time a current athlete has become a shareholder in Prenetics.

IM8, a premium supplements brand co-founded by David Beckham, has achieved remarkable growth since its December 2024 launch, generating over $50 million in Annual Recurring Revenue and serving 60,000+ customers with more than 5 million supplement servings. The company's NSF Certified for Sport® Daily Ultimate Essentials product has been part of Sabalenka's daily routine since early 2025, contributing to her successful season including titles in Brisbane, Miami, and Madrid.

Prenetics (NASDAQ: PRE) has become the first healthcare company to implement a major Bitcoin treasury strategy, purchasing 187.42 BTC worth $20 million at an average price of $106,712 per Bitcoin. The company appointed Andy Cheung, former COO of OKEx, to its Board of Directors to oversee this initiative. With a strengthened balance sheet of $117M and zero debt, Prenetics plans to allocate the majority of its assets to Bitcoin. The company's core business is performing well, with projected 2025 revenue of $80-100M and profitability expected in Q4 2025. Their IM8 Health platform is showing strong growth with $50M+ ARR and 55,000 customers. The strategy includes institutional partnerships, alpha-generating approaches, and operational Bitcoin integration across their consumer platforms. The company is supported by crypto industry leaders including Tracy Hoyos Lopez and Raphael Strauch, founder of TOKEN2049.

Prenetics Global Limited (NASDAQ: PRE) has announced the divestment of ACT Genomics to Delta Electronics in a transaction valued at up to US$71.78 million. Prenetics will receive approximately US$46 million in gross proceeds, boosting its pro-forma cash reserves to US$86 million and short-term assets to US$117 million. The company maintains a debt-free balance sheet and raised its FY2025 revenue outlook to US$80-100 million from US$73-85 million. Following the divestment, Prenetics will focus on three consumer health brands: IM8 (premium supplements), CircleDNA (DNA testing), and Europa (sports nutrition). The company's Q1 2025 revenue reached $14.4 million, a 336.5% YoY increase. IM8, launched just six months ago, has acquired over 55,000 customers with a 91% subscription rate and presence in 31 countries. Additionally, Prenetics holds a 35% stake in Insighta valued at $70 million.

Prenetics reported strong Q1 2025 financial results with revenue from continuing operations reaching $17.3M, up 169.9% YoY. Consumer business revenue (excluding ACT Genomics) grew 336.5% to $14.4M. The company raised its FY2025 revenue outlook to $80-100M from previous $73-85M. IM8, their flagship product, contributed $5.7M in Q1 with 55,000+ customers and 4.9M servings delivered across 31 countries. Q2 IM8 revenue is projected at $8.5M, a 50% QoQ increase. The company maintains a strong financial position with $78M in cash and short-term assets, remaining debt-free. Prenetics announced plans to implement a crypto strategy and Bitcoin adoption as part of their treasury management approach. The company expects to conclude its strategic review of ACT Genomics soon.

IM8, the premium supplement brand co-founded by David Beckham, hosted 'IM8 Vibrante' at Miami Beach's Faena Theater on April 09, 2025. The event gathered approximately 150 wellness influencers, creators, and medical advisors to showcase the brand's approach to science-backed wellness solutions.

Key highlights included:

• Presentations from Scientific Advisory Board members including Dr. Amy Shah, Dr. James DiNicolantonio, and Dr. Jeremy London on longevity science
• Dr. Jim Green's update on IM8's space aging experiment with SpaceX and Oxford University, with a new phase launching April 21, 2025
• Showcase of IM8's flagship product 'Daily Ultimate Essentials'

The event featured discussions on wellness innovation, scientific advancement, and making elite health accessible to all, while strengthening IM8's community of health and wellness advocates.